Surrozen Q3: DUET Phase 2a Expanded to 150 Patients, Cash Runway Into 2029
SRZN has more than doubled off its 52-week low of $11.51 on light trading volume (0.2× avg).
Summary
Surrozen reported a $129.7 million Q3 net loss that was mostly non-cash warrant and tranche remeasurement, while expanding its DUET Phase 2a DME trial to 150 patients and extending its cash runway into 2029 on roughly $220.3 million pro forma cash.
Key Events · Earnings and Guidance · SRZN
-
DUET Phase 2a Expanded to 150 Patients
Enrollment in the randomized Phase 2a portion of DUET grows from approximately 60 to 150 DME patients, testing two dose levels of SZN-8141 against Vabysmo in both treatment-naïve and treatment-experienced patients.
-
First Patient Dosed in Phase 1b
The open-label single-ascending-dose Phase 1b portion has begun dosing; topline Phase 1b data are expected in the second half of 2027 and Phase 2a topline in 2028.
-
Net Loss Is Non-Cash Remeasurement
The $129.7 million Q3 net loss includes $113.0 million of non-cash losses on changes in fair value of tranche and warrant liabilities, driven primarily by the increase in the stock price — not a cash outflow and not new dilution.
-
Cash Runway Extended Into 2029
Pro forma cash was approximately $220.3 million as of September 30, 2026, after the $95.1 million gross PIPE tranche, $29.8 million in ATM net proceeds and $1.1 million from warrant exercises, funding the expanded DUET study and initial Phase 1b work on SZN-8143.
Analysis · SRZN · Life Sciences
The headline $129.7 million net loss is almost entirely accounting noise: $113.0 million of it is non-cash mark-to-market on the tranche and warrant liabilities, which rose because the stock price rose, not because cash left the company. What actually matters is the operating picture — R&D spend of $10.8 million for the quarter and a pro forma cash balance of roughly $220.3 million after the October PIPE tranche and ATM sales, enough to fund operations into 2029. Management is putting that money to work by expanding the DUET Phase 2a from about 60 to 150 patients, a bigger and more expensive trial but one that should produce a more credible dataset against Vabysmo. The trade-off is timing: Phase 1b topline now lands in the second half of 2027 and Phase 2a in 2028, so investors wait longer for the readout that would actually reprice the stock.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SRZN was trading at $32.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $376.1M. The 52-week trading range was $11.51 to $37.83. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.